IRCT20200116046154N1已完成未知
Anti-atherosclerosis effects of 12 weeks high intensity interval and aerobic training on serum levels salusin-a and -ß, nitric oxide, inflammatory markers and lipid profile in overweight and obese childrens
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 9 years 至 12 years（—）
- 性别
- Male
入选标准
- •Ages 9 to 12 years
- •Body mass index between 19.1-26.2
- •No drug treatment
- •?NO chronic diseases such as diabetes, metabolic syndrome (systolic blood pressure 130 mm Hg or diastolic blood pressure 85 mm Hg, waist circumference greater than 102 cm and fasting glucose 110 mm Hg), hormone, orthopedic
- •Not participating in any regular training program (except for exercise ring) within 6 months prior to entering the study
- •The subjects must be boys
排除标准
- •Voluntary withdrawal by participants for any reason.
- •Acute infectious diseases such as influenza during research.
- •Two consecutive absentee sessions and three non-consecutive sessions during the time of the research run.
- •Acute Injury Due to Practice During Research.
研究者
相似试验
未知
不适用
Clinical study on anti-atherosclerotic effect of azelnidipine/amlodipine in the hypertensive patients with type 2 diabetesHypertensionJPRN-UMIN000000495Advanced Medicine Study Group in Kyushu Island150
已完成
不适用
Effect of prolonged cholesterol lowering treatment on trained immunity of monocytes in patients with elevated levels of LDL-cholesterolCardiovascular diseasehypercholesterolemiaNL-OMON49515Radboud Universitair Medisch Centrum30
尚未招募
不适用
Antiatherogenic Effect of Combination Therapy Calcium Channel Blocker with Renin-Angiotensin System Inhibitor on Hypertensive PatientsHypertensionJPRN-UMIN000003474Tokushima University60
进行中（未招募）
不适用
PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan - PRIMAPatients at high risk for CVDEUCTR2005-005563-28-DEniversity Clinic Essen160
招募中
2 期
Do stAtins faVourably modify atherosclerotIc plaque in patients with differeNt levels of polygenic Cardiovascular (CV) rIsk?Coronary atherosclerosisPolygenic riskCardiovascular - Coronary heart diseaseCardiovascular diseaseACTRN12620001166965Monash University600